FDA draft guidance outlines appropriate use of tissue biopsies in clinical trials
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesClinical TrialsGuidanceMedical DevicesPharmaceuticalsProduct developmentRisk managementUnited StatesUS Food and Drug Administration (FDA)